Compare POWI & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWI | DNTH |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 1997 | N/A |
| Metric | POWI | DNTH |
|---|---|---|
| Price | $47.88 | $48.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $61.00 | ★ $70.22 |
| AVG Volume (30 Days) | 906.3K | ★ 941.0K |
| Earning Date | 02-05-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $445,550,000.00 | $3,078,000.00 |
| Revenue This Year | $7.93 | N/A |
| Revenue Next Year | $7.60 | N/A |
| P/E Ratio | $142.32 | ★ N/A |
| Revenue Growth | ★ 10.49 | N/A |
| 52 Week Low | $30.86 | $13.37 |
| 52 Week High | $68.20 | $57.50 |
| Indicator | POWI | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 69.34 | 53.21 |
| Support Level | $44.22 | $48.86 |
| Resistance Level | $48.57 | $54.85 |
| Average True Range (ATR) | 1.87 | 3.27 |
| MACD | 0.09 | 0.13 |
| Stochastic Oscillator | 87.63 | 39.56 |
Power Integrations Inc designs, develops, and markets analog and mixed-signal integrated circuits (ICs) and other electronic components and circuitry used in high-voltage power conversion. Products are used in power converters that convert electricity from a high-voltage source to the type of power required for a specified downstream use. Products are used in electronic products including mobile phones, computing and networking equipment, appliances, electronic utility meters, battery-powered tools, industrial controls, home automation, or Internet of Things applications such as networked thermostats, power strips, and security devices. Geographically, the company generates maximum revenue from China and Hong Kong.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.